Syndax Pharmaceuticals Inc (OQ:SNDX)
Business Focus: Biotechnology & Medical Research
May 09, 2024 07:00 am ET
Syndax Announces Participation at the Bank of America Securities 2024 Health Care Conference
WALTHAM, Mass., May 9, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of the Syndax management team will participate in a fireside chat at the Bank of America Securities 2024 Health Care Conference on Thursday, May 16, 2024, at 8:00 a.m. PT/ 11:00 a.m. ET.
May 08, 2024 07:06 am ET
Syndax Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update
– NDA filing for revumenib in R/R KMT2Ar acute leukemia granted Priority Review under RTOR; PDUFA action date set for September 26, 2024 –
May 03, 2024 04:05 pm ET
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
WALTHAM, Mass., May 3, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on May 1, 2024 the Company granted inducement awards to purchase up to 100,600 shares of common stock to six new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subj
May 01, 2024 07:00 am ET
Syndax to Announce First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024
WALTHAM, Mass., May 1, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will report its first quarter 2024 financial results and provide a business update on Wednesday, May 8, 2024.
Apr 10, 2024 04:05 pm ET
Syndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum
WALTHAM, Mass., April 10, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, will participate in a fireside chat at the at Stifel 2024 Virtual Targeted Oncology Forum on Wednesday, April 17, 2024, at 11:00 a.m. ET.
Apr 08, 2024 07:00 am ET
Syndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session
– Consistent safety and efficacy profiles across adult and pediatric populations –
Apr 05, 2024 04:05 pm ET
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
WALTHAM, Mass., April 5, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on April 1, 2024 the Company granted inducement awards to purchase up to 164,200 shares of common stock to ten new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months,
Mar 28, 2024 07:00 am ET
Syndax Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia
– Topline data expected in 4Q24 could support sNDA filing in 1H25 –
Mar 26, 2024 04:05 pm ET
Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute Leukemia
– PDUFA action date set for September 26, 2024 –
Feb 26, 2024 06:00 am ET
Syndax Announces Participation at Two Upcoming Investor Conferences
WALTHAM, Mass., Feb. 26, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in the following sessions at two upcoming investor conferences:
Feb 20, 2024 03:05 pm ET
Syndax to Announce Fourth Quarter and Year-end 2023 Financial Results and Host Conference Call and Webcast on February 27, 2024
WALTHAM, Mass., Feb. 20, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will report its fourth quarter and year-end 2023 financial results and provide a business update on Tuesday, February 27, after the close of the U.S. financial markets.
Feb 02, 2024 03:05 pm ET
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
WALTHAM, Mass., Feb. 2, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on February 1, 2024 the Company granted inducement awards to purchase up to 127,300 shares of common stock to eight new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 mont
Feb 01, 2024 03:10 pm ET
Syndax Announces Participation at Two Upcoming Investor Conferences
WALTHAM, Mass., Feb. 1, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in two upcoming investor conferences:
Jan 05, 2024 03:05 pm ET
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
WALTHAM, Mass., Jan. 5, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on January 1, 2024 the Company granted inducement awards to purchase up to 8,600 shares of common stock to one new employee under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, su
Jan 02, 2024 03:05 pm ET
Syndax Announces Presentation at 42nd Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass., Jan. 2, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 at 5:15 p.m. PT/ 8:15 p.m. ET.
Jan 02, 2024 06:00 am ET
Syndax Highlights Recent Updates and Anticipated 2024 Milestones
– BLA submitted for axatilimab in chronic graft-versus-host disease; Syndax exercised option to co-commercialize axatilimab in the U.S. with Incyte –
Dec 19, 2023 03:16 pm ET
Syndax Announces Closing of Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares
WALTHAM, Mass., Dec. 19, 2023 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the closing of its previously announced underwritten public offering of 12,432,431 shares of its common stock, which includes the exercise in full of the underwriters' option to purchase 1,621,621 additional shares. The public offering price of each share of common stock was $18.50. The aggregate gross proceeds to Syndax from this offering, before deducting
Dec 14, 2023 10:07 pm ET
Syndax Announces Pricing of $200 Million Public Offering of Common Stock
WALTHAM, Mass., Dec. 14, 2023 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax" or the "Company") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the pricing of an underwritten public offering of 10,810,810 shares of its common stock. The public offering price of each share of common stock is $18.50. The aggregate gross proceeds from this offering are expected to be approximately $200.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by Syndax. In additi
Dec 14, 2023 03:00 pm ET
Syndax Announces Proposed $150 Million Public Offering of Common Stock
WALTHAM, Mass., Dec. 14, 2023 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax" or the "Company") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it plans to offer and sell, subject to market and other conditions, $150 million of shares of its common stock in an underwritten public offering. Syndax also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock sold in the public offering. All of the shares in the proposed offering are
Dec 12, 2023 11:00 am ET
Syndax Presents Positive Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at Late-Breaking Oral Presentation During 65th ASH Annual Meeting
– Pivotal AUGMENT-101 trial met its primary endpoint at interim analysis of the pooled KMT2Ar AML and ALL cohorts (p-value = 0.0036); CR/CRh rate consistent across adult and pediatric patients –
Dec 11, 2023 06:30 am ET
Syndax Announces Positive Data for Revumenib in Patients with Acute Leukemias from the BEAT AML, SAVE AML and AUGMENT-102 Phase 1 Combination Trials
- Data collectively highlight revumenib's combination potential with current standard of care agents and support advancement into pivotal combination trials in the frontline setting -
Dec 10, 2023 05:00 pm ET
Incyte and Syndax Present Additional Data from Positive AGAVE-201 Trial at ASH Plenary Session Showing Axatilimab Efficacy Including Durable Responses in Chronic Graft-Versus-Host Disease
Incyte (Nasdaq:INCY) and Syndax Pharmaceuticals (Nasdaq:SNDX) today announced the full results from the pivotal Phase 2 AGAVE-201 trial of axatilimab, an anti-CSF-1R antibody, in adult and pediatric patients with refractory chronic graft-versus-host disease (GVHD) who had received at least two prior lines of systemic therapy. These data are featured today in the Plenary Scientific Session (Abstract #1) at the 65th American Society of Hematology Annual Meeting 2023 (ASH 2023), held December 9-12, 2023, in San Diego and virtually.
Dec 04, 2023 06:00 am ET
Syndax to Host Investor Event to Discuss Axatilimab and Revumenib Data Updates at 65th ASH Annual Meeting
WALTHAM, Mass., Dec. 4, 2023 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that the Company will host an in-person investor event, along with a live webcast, on Monday, December 11, 2023, at 7:00 a.m. PT / 10:00 a.m. ET during the 65th American Society of Hematology (ASH) Annual Meeting in San Diego, California.
Dec 01, 2023 03:05 pm ET
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
WALTHAM, Mass., Dec. 1, 2023 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on December 1, 2023 the Company granted inducement awards to purchase up to 158,000 shares of common stock to nine new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 month
Nov 21, 2023 08:00 am ET
Syndax Announces Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Selected as Late-Breaking Presentation at the 65th ASH Annual Meeting
WALTHAM, Mass., Nov. 21, 2023 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that data from the pivotal trial of revumenib, the Company's highly selective, oral menin inhibitor, will be featured in a late-breaking presentation at the 65th American Society of Hematology (ASH) Annual Meeting being held December 9-12, 2023 in San Diego, California. A copy of the abstract is now available online via the ASH website at www.hematology.org.
Nov 07, 2023 06:00 am ET
Syndax Announces Participation at Stifel Healthcare Conference
WALTHAM, Mass., Nov. 7, 2023 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, will participate in a fireside chat at the Stifel Healthcare Conference on Tuesday, November 14, 2023, at 4:45 p.m. ET.
Nov 03, 2023 04:05 pm ET
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
WALTHAM, Mass., Nov. 3, 2023 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on November 1, 2023 the Company granted inducement awards to purchase up to 169,600 shares of common stock to ten new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months
Nov 02, 2023 04:05 pm ET
Syndax Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Clinical and Business Update
– NDA submission initiated for revumenib in R/R KMT2Ar acute leukemia under RTOR –
Nov 02, 2023 09:00 am ET
Syndax Announces Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease to Be Featured in Plenary Session at the 65th ASH Annual Meeting
– Results support axatilimab's promising safety and efficacy profile, and reinforce its potential as a first-in-class CSF-1R monoclonal antibody in chronic graft-versus-host disease –
Nov 02, 2023 09:00 am ET
Syndax Announces Updated Data Supporting Impressive Clinical Profile of Revumenib in Genetically-Defined Acute Leukemias to Be Presented at the 65th ASH Annual Meeting
– Additional data from pivotal AUGMENT-101 trial in R/R KMT2Ar acute leukemia further highlight revumenib's potential best-in-class profile –
Oct 26, 2023 07:00 am ET
Syndax to Announce Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 2, 2023
WALTHAM, Mass., Oct. 26, 2023 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will report its third quarter 2023 financial results and provide a business update on Thursday, November 2, after the close of the U.S. financial markets.
Oct 24, 2023 07:00 am ET
Syndax to Initiate NDA Submission of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Under FDA's Real-Time Oncology Review Program
– Solidifies first-to-market potential for revumenib –
Oct 06, 2023 04:05 pm ET
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
WALTHAM, Mass., Oct. 6, 2023 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on October 1, 2023 the Company granted inducement awards to purchase up to 121,150 shares of common stock to eight new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 month
Oct 02, 2023 07:00 am ET
Syndax Announces Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Meets Primary Endpoint and Stopped Early for Efficacy Following Protocol-Defined Interim Analysis
– Trial met its primary endpoint with a CR/CRh rate of 23% at interim analysis of the pooled KMT2Ar AML and ALL cohorts (p-value = 0.0036); an additional 14% of patients proceeded to transplant without achieving CR/CRh –
Sep 29, 2023 04:05 pm ET
Syndax to Announce Topline Results from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia and Host an Investor Call on October 2, 2023
WALTHAM, Mass., Sept. 29, 2023 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will host a conference call and live webcast to share topline results from the pivotal AUGMENT-101 trial in patients with relapsed/refractory KMT2Ar acute leukemia on Monday, October 2, 2023 at 8:00 a.m. ET.
Jul 25, 2023 07:00 am ET
Syndax to Announce Second Quarter 2023 Financial Results and Host Conference Call and Webcast on August 3, 2023
WALTHAM, Mass., July 25, 2023 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will report its second quarter 2023 financial results and provide a business update on Thursday, August 3, after the close of the U.S. financial markets.
Jul 24, 2023 09:31 am ET
Thinking about trading options or stock in Cinemark Holdings, Amazon.com, SoundHound AI, Posco Holdings, or Syndax Pharmaceuticals?
NEW YORK, July 24, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CNK, AMZN, SOUN, PKX, and SNDX.
Jul 24, 2023 07:00 am ET
Syndax and Incyte Announce Positive Topline Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease
– Trial met its primary endpoint across all cohorts with an overall response rate (ORR) of 74% at a dose of 0.3 mg/kg administered every two weeks –
Jul 07, 2023 04:05 pm ET
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
WALTHAM, Mass., July 7, 2023 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on July 1, 2023 the Company granted inducement awards to purchase up to 31,400 shares of common stock to two new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 month
Jun 02, 2023 04:05 pm ET
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
WALTHAM, Mass., June 2, 2023 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on June 1, 2023 the Company granted inducement awards to purchase up to 397,900 shares of common stock to eighteen new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36
May 24, 2023 07:00 am ET
Syndax Announces Participation at Two Upcoming Investor Conferences
WALTHAM, Mass., May 24, 2023 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in two upcoming investor conferences:
May 08, 2023 04:05 pm ET
Syndax Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Clinical and Business Update
– Topline data from the pivotal AGAVE-201 trial of axatilimab in cGVHD on track for mid-2023 –
May 04, 2023 04:05 pm ET
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
WALTHAM, Mass., May 4, 2023 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on May 1, 2023 the Company granted inducement awards to purchase up to 272,000 shares of common stock to fifteen new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 mo
May 01, 2023 07:00 am ET
Syndax to Announce First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 8, 2023
WALTHAM, Mass., May 1, 2023 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will report its first quarter 2023 financial results and provide a business update on Monday, May 8, after the close of the U.S. financial markets.
Apr 13, 2023 04:05 pm ET
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
WALTHAM, Mass., April 13, 2023 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that in connection with the hiring, announced on April 10, 2023, of Neil Gallagher, M.D., Ph.D., as President, Head of Research and Development, Dr. Gallagher received an inducement award to purchase up to 250,000 shares of common stock. The stock option has an exercise price per share of $19.35, the closing price of the Company's common stock on the Nasdaq Global Select Market on April 10
Apr 07, 2023 04:05 pm ET
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
WALTHAM, Mass., April 7, 2023 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on April 3, 2023 the Company granted inducement awards to purchase up to 121,100 shares of common stock to six new employees under the Company's 2023 Inducement Plan. The stock options have an exercise price per share of $20.91, the closing price of the Company's common stock on the Nasdaq Global Select Market on April 3, 2023 and will vest over four years, with 25% of the underlying s
Mar 30, 2023 07:00 am ET
Syndax Pharmaceuticals Announces Appointment of Neil Gallagher, M.D., Ph.D. as President, Head of Research and Development
- Neil Gallagher, M.D., Ph.D. brings to Syndax over 20 years of experience as a leading oncology drug developer -
Mar 15, 2023 04:05 pm ET
Syndax Pharmaceuticals Announces Two Publications in Nature of Data from the Phase 1 Portion of AUGMENT-101 in Acute Leukemia Patients
WALTHAM, Mass., March 15, 2023 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX) today announced that data from the Phase 1 portion of the ongoing Phase 1/2 AUGMENT-101 trial of revumenib in patients with nucleophosmin mutant (mNPM1) and KMT2A-rearranged (KMT2Ar) relapsed/refractory (R/R) acute leukemia and an analysis describing MEN1 mutations observed in the study have been published in the journal Nature. Revumenib is the Company's highly selective, oral menin inhibitor.
Feb 27, 2023 10:15 am ET
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Syndax Pharmaceuticals, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors
NEW YORK, Feb. 27, 2023 /PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX).
Feb 21, 2023 06:00 am ET
Syndax to Announce Fourth Quarter and Year-end 2022 Financial Results and Host Conference Call and Webcast on February 28, 2023
WALTHAM, Mass., Feb. 21, 2023 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will report its fourth quarter and year-end 2022 financial results and provide a business update on Tuesday, February 28, after the close of the U.S. financial markets.
Feb 14, 2023 06:00 am ET
Syndax Announces Participation at Upcoming Investor Conferences
WALTHAM, Mass., Feb. 14, 2023 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in the upcoming investor conferences:
Jan 04, 2023 06:00 am ET
Syndax Announces Presentation at 41st Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass., Jan. 4, 2023 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 10:30 a.m. PT/ 1:30 p.m. ET.
Dec 14, 2022 03:05 pm ET
Syndax Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
WALTHAM, Mass., Dec. 14, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the closing of its previously announced underwritten public offering of 7,840,909 shares of its common stock at a price to the public of $22.00 per share. This includes the exercise in full by the underwriters of their option to purchase up to 1,022,727 additional shares of common stock. The aggregate gross proceeds to Syndax from this offering were $172.5
Dec 10, 2022 04:00 pm ET
Syndax Announces Positive Updated Data from Phase 1 Portion of AUGMENT-101 Trial of Revumenib in Patients with Acute Leukemias During Oral Presentations at 64th ASH Annual Meeting
- 30% CR/CRh rate in efficacy evaluable population; 27% CR/CRh rate observed in both mNPM1 and KMT2Ar (MLLr) R/R acute leukemia patients treated at RP2D -
Dec 08, 2022 04:06 pm ET
Syndax Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
WALTHAM, Mass., Dec. 8, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that in connection with the hiring, announced on December 5, 2022, of Steve M. Sabus as Chief Commercial Officer, Mr. Sabus received an inducement award to purchase up to 220,000 shares of common stock. The stock option has an exercise price per share of $25.44, the closing price of the Company's common stock on the Nasdaq Global Select Market on December 5,
Dec 06, 2022 08:38 pm ET
Syndax Announces Pricing of $150 Million Public Offering of Common Stock
WALTHAM, Mass., Dec. 6, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the pricing of an underwritten public offering of 6,818,182 shares of its common stock. The public offering price of each share of common stock is $22.00. The aggregate gross proceeds from this offering are expected to be approximately $150.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by Syndax. In ad
Dec 06, 2022 03:30 pm ET
Syndax Announces Proposed $150 million Public Offering of Common Stock
WALTHAM, Mass., Dec. 6, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it plans to offer and sell, subject to market and other conditions, $150 million of shares of its common stock in an underwritten public offering. Syndax also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock sold in the public offering. All of the shares in the proposed offerin
Dec 05, 2022 06:15 am ET
Syndax Announces U.S. FDA Breakthrough Therapy Designation Granted for Revumenib for the Treatment of Adult and Pediatric Patients with Relapsed or Refractory KMT2A- Rearranged (MLLr) Acute Leukemia
-- Revumenib is the first and only investigational treatment for R/R KMT2Ar acute leukemia to receive Breakthrough Therapy Designation --
Dec 05, 2022 06:00 am ET
Syndax Pharmaceuticals and Incyte Announce Axatilimab Phase 1/2 Data in Patients with Chronic Graft-Versus-Host Disease Published in the Journal of Clinical Oncology
– Treatment with axatilimab resulted in an overall response rate (ORR) of 67% across all patients; and an ORR of 82% in patients dosed at 1 mg/kg every 2 weeks in the Phase 2 portion of the trial –
Dec 02, 2022 06:00 am ET
Syndax Pharmaceuticals Announces Appointment of Steve Sabus as Chief Commercial Officer
WALTHAM, Mass., Dec. 2, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the appointment of Steve Sabus to the role of Chief Commercial Officer, effective December 5, 2022. Mr. Sabus brings to Syndax more than 30 years of commercial experience launching drugs and building sales and marketing organizations within the biopharmaceutical industry. As Chief Commercial Officer, Mr. Sabus will oversee all commercial functions, including the development of critical launc
Nov 21, 2022 06:00 am ET
Syndax Announces Participation at Evercore ISI Annual HealthCONx Conference
WALTHAM, Mass., Nov. 21, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in a fireside chat at the Evercore ISI Annual HealthCONx Conference on Wednesday, November 30, 2022, at 3:30 p.m. ET.
Nov 03, 2022 04:05 pm ET
Syndax Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Clinical and Business Update
– Updated positive data from Phase 1 portion of AUGMENT-101 trial demonstrates CR/CRh rate of 30% and a median durability of response of 9.1 months –
Nov 03, 2022 09:00 am ET
Syndax Announces Positive Updates to Clinical Activity and Durable Remissions in Phase 1 Portion of AUGMENT-101 Trial of Revumenib in Patients with Acute Leukemias
- 30% CR/CRh rate and 53% ORR in R/R acute leukemia patients with NPM1 or MLLr (KMT2Ar) mutations; no discontinuations due to treatment-related adverse events -
Oct 27, 2022 07:00 am ET
Syndax to Announce Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 3, 2022
WALTHAM, Mass., Oct. 27, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will report its third quarter 2022 financial results and provide a business update on Thursday, November 3, after the close of the U.S. financial markets.
Aug 08, 2022 04:05 pm ET
Syndax Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Clinical and Business Update
– On track to report topline data from revumenib and axatilimab pivotal programs starting in 1H23 –
Aug 02, 2022 07:00 am ET
Syndax to Announce Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 8, 2022
WALTHAM, Mass., Aug. 2, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will report its second quarter 2022 financial results on Monday, August 8, after the close of the U.S. financial markets.
Jun 16, 2022 04:30 pm ET
Syndax Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
WALTHAM, Mass., June 16, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that in connection with the hiring, announced on June 13, 2022, of Keith A. Goldan as Chief Financial Officer, Mr. Goldan received an inducement award to purchase up to 230,000 shares of common stock. The stock option has an exercise price per share of $15.60, the closing price of the Company's common stock on the Nasdaq Global Select Market on June 13, 202
Jun 13, 2022 07:30 am ET
Syndax Pharmaceuticals Announces Appointment of Keith A. Goldan as Chief Financial Officer
WALTHAM, Mass., June 13, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the appointment of Keith A. Goldan to the role of Chief Financial Officer, effective immediately. Mr. Goldan, who brings to Syndax nearly thirty years of leadership and operational experience at several pharmaceutical, biotechnology, and medical technology companies, most recently served as Chief Financial Officer at Optinose®, where he helped build the inf
May 26, 2022 07:00 am ET
Syndax Announces Participation at Two Upcoming Investor Conferences
WALTHAM, Mass., May 26, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in two upcoming investor conferences:
May 11, 2022 07:00 am ET
Syndax Announces Participation at Citi's Biopharma Virtual Co-Panel Day
WALTHAM, Mass., May 11, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, will participate in a panel discussion on targeted oncology at Citi's Biopharma Virtual Co-Panel Day on Wednesday, May 18, 2022 at 1:30 p.m. ET.
May 09, 2022 04:05 pm ET
Syndax Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Clinical and Business Update
– Topline data from revumenib (SNDX-5613) and axatilimab pivotal programs expected starting in 1H23; Company remains on track for two FDA filings in 2023 –
May 02, 2022 07:00 am ET
Syndax to Announce First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 9, 2022
WALTHAM, Mass., May 2, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will release its first quarter 2022 financial results on Monday, May 9, after the close of the U.S. financial markets.
Mar 04, 2022 03:05 pm ET
Syndax Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
WALTHAM, Mass., March 4, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that in connection with the hiring, announced on March 1, 2022, of Catherine Madigan, M.D., as Chief Medical Officer, Dr. Madigan received an inducement award to purchase up to 180,000 shares of common stock. The stock option has an exercise price per share of $16.06, the closing price of the Company's common stock on the Nasdaq Global Select Market on Marc
Mar 01, 2022 03:05 pm ET
Syndax Pharmaceuticals Reports Fourth Quarter 2021 Financial Results and Provides Clinical and Business Update
WALTHAM, Mass., March 1, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the fourth quarter ended December 31, 2021. In addition, the Company provided a clinical and business update.
Mar 01, 2022 03:01 pm ET
Syndax Pharmaceuticals Announces Appointment of Kate Madigan, M.D., as Chief Medical Officer
WALTHAM, Mass., March 1, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the appointment of Kate Madigan, M.D., to the role of Chief Medical Officer, effective immediately. Dr. Madigan, who brings to Syndax over 20 years of clinical hematology expertise and broad experience in the design and execution of early to late-stage clinical programs across oncology and rare diseases, will lead the Company's clinical development strategy
Feb 28, 2022 06:00 am ET
Syndax Announces Participation at Two Upcoming Investor Conferences
WALTHAM, Mass., Feb. 28, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in two upcoming investor conferences:
Feb 08, 2022 06:30 am ET
Soligenix to Present at the 2022 BIO CEO & Investor Conference
PRINCETON, N.J., Feb. 8, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its President and Chief Executive Officer, Christopher J. Schaber, PhD, will deliver a corporate presentation at the BIO CEO & Investor Conference taking place February 14-17, 2022. The presentation will be available to registered conference attendees for on-demand viewing beginning February 11, 2022 via the event
Feb 03, 2022 03:01 pm ET
Syndax Pharmaceuticals Announces Transition of Michael A. Metzger to Chief Executive Officer; Briggs W. Morrison, M.D., to Assume Role of President, Head of Research & Development
WALTHAM, Mass., Feb. 3, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger, President and Chief Operating Officer, will transition to the role of Chief Executive Officer, effective today. Briggs W. Morrison, M.D., Chief Executive Officer, will transition to the role of President, Head of Research and Development (R&D). Mr. Metzger and Dr. Morrison will remain on the Company's Board of Directors. Both Mr.
Jan 20, 2022 06:00 am ET
Syndax Announces Presentation at B. Riley Securities' 2022 Oncology Conference
WALTHAM, Mass., Jan. 20, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in a fireside chat at B. Riley Securities' 2022 Oncology Conference on Thursday, January 27, 2022 at 12:00 p.m. ET.
Jan 07, 2022 06:00 am ET
Syndax Announces Presentation at 40th Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass., Jan. 7, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Briggs W. Morrison, M.D., Chief Executive Officer of Syndax, will present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 08:15 a.m. ET.
Dec 22, 2021 06:00 am ET
Syndax Announces Orphan Drug Designation Granted to SNDX-5613 by European Commission for the Treatment of Acute Myeloid Leukemia
WALTHAM, Mass., Dec. 22, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that the European Commission has granted Orphan Drug Designation to SNDX-5613, the Company's highly selective oral menin inhibitor, for the treatment of acute myeloid leukemia (AML).
Dec 20, 2021 03:05 pm ET
Syndax Announces Closing of Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares
WALTHAM, Mass., Dec. 20, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the closing of its previously announced underwritten public offering of 3,802,144 shares of its common stock, which includes the exercise in full of the underwriters' option to purchase 645,000 additional shares, and to certain investors, pre-funded warrants to purchase 1,142,856 shares of its common stock at an exercise price of $0.0001. The public offerin
Dec 15, 2021 10:37 pm ET
Syndax Announces Pricing of $75.3 Million Public Offering
WALTHAM, Mass., Dec. 15, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the pricing of an underwritten public offering of 3,157,144 shares of its common stock, and to certain investors pre-funded warrants to purchase 1,142,856 shares of its common stock at an exercise price of $0.0001. The public offering price of each share of common stock is $17.50 and the public offering price of each pre-funded warrant is $17.4999 per under
Dec 15, 2021 03:29 pm ET
Syndax Announces Proposed Public Offering of Common Stock
WALTHAM, Mass., Dec. 15, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it plans to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. Syndax may, in lieu of common stock, offer and sell to certain investors pre-funded warrants to purchase shares of its common stock in the underwritten public offering. Syndax also expects to grant the underwriters a 30-day
Dec 13, 2021 01:45 pm ET
Syndax Pharmaceuticals Announces Additional Positive Data Demonstrating Continued Robust Clinical Activity with Durable Responses in Phase 1 Portion of AUGMENT-101 Trial of SNDX-5613
WALTHAM, Mass., Dec. 13, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced updated positive data from the Phase 1 dose escalation portion of the AUGMENT-101 trial of SNDX-5613 in patients with mutant nucleophosmin (mNPM1) or mixed lineage leukemia rearranged (MLLr) relapsed/refractory (R/R) acute leukemias. SNDX-5613 is the Company's highly selective oral menin inhibitor. The data are being featured during an oral session at the 6
Dec 11, 2021 01:00 pm ET
Syndax Pharmaceuticals Announces Updated Positive Data Demonstrating Broad Activity and Tolerability of Axatilimab in Patients with Chronic Graft-Versus-Host Disease
WALTHAM, Mass., Dec. 11, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced updated positive data from its Phase 1/2 trial of axatilimab in patients with recurrent or refractory chronic graft-versus-host disease (cGVHD) despite two or more prior lines of therapy. Axatilimab is the Company's anti-CSF-1R monoclonal antibody. The data are being featured during an oral session at the 63rd American Society of Hematology (ASH) Annual Mee
Dec 09, 2021 03:05 pm ET
Syndax Pharmaceuticals Announces Closing of Global Collaboration and License Agreement for Axatilimab
WALTHAM, Mass., Dec. 9, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX) announced today that the Hart-Scott-Rodino (HSR) antitrust waiting period had expired and that the parties closed the exclusive worldwide collaboration and license agreement between Syndax and Incyte to develop and commercialize axatilimab, Syndax's anti-CSF-1R monoclonal antibody.
Nov 15, 2021 03:05 pm ET
Syndax Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Clinical and Business Update
WALTHAM, Mass., Nov. 15, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the third quarter ended September 30, 2021. In addition, the Company provided a clinical and business update.
Nov 08, 2021 06:00 am ET
Syndax to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 15, 2021
WALTHAM, Mass., Nov. 8, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its third quarter 2021 financial results on Monday, November 15, after the close of the U.S. financial markets.
Nov 04, 2021 09:23 am ET
Syndax Pharmaceuticals to Present Updated Data from SNDX-5613 and Axatilimab Clinical Programs During Oral Sessions at 63rd ASH Annual Meeting
WALTHAM, Mass., Nov. 4, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that updated data from both of its ongoing SNDX-5613 and axatilimab programs will be featured during oral sessions at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition being held December 11-14, 2021. SNDX-5613 is the Company's highly selective oral menin inhibitor. Axatilimab is Syndax's anti-CSF-1R monoclonal antibody.
Sep 27, 2021 09:31 am ET
Thinking about buying stock in Syndax Pharmaceuticals, Tellurian, RA Medical Systems, AST SpaceMobile, or Aditxt?
NEW YORK, Sept. 27, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SNDX, TELL, RMED, ASTS, and ADTX.
Sep 27, 2021 06:00 am ET
Syndax Pharmaceuticals and Incyte Announce Global Collaboration to Develop and Commercialize Axatilimab for Chronic Graft-Versus-Host Disease and Other Fibrotic Diseases
WALTHAM, Mass. and WILMINGTON, Del., Sept. 27, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX) and Incyte (Nasdaq: INCY) announced today that they have entered into an exclusive worldwide collaboration and license agreement to develop and commercialize axatilimab, Syndax's anti-CSF-1R monoclonal antibody.
Sep 15, 2021 04:01 pm ET
Syndax Appoints Martin H. Huber, M.D., to its Board of Directors
WALTHAM, Mass., Sept. 15, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the expansion of its Board of Directors to nine members with the appointment of Martin H. Huber, M.D., effective today. Dr. Huber has over 20 years of academic, biotechnology, and pharmaceutical drug development experience, currently serving as the President of R&D and Chief Medical Officer of Xilio Therapeutics, Inc.
Sep 02, 2021 07:00 am ET
Syndax Announces Participation at Three Upcoming Investor Conferences
WALTHAM, Mass., Sept. 2, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in three upcoming virtual investor conferences:
Aug 09, 2021 04:01 pm ET
Syndax Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Clinical and Business Update
WALTHAM, Mass., Aug. 9, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the second quarter ended June 30, 2021. In addition, the Company provided a clinical and business update.
Aug 02, 2021 07:00 am ET
Syndax to Announce Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 9, 2021
WALTHAM, Mass., Aug. 2, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its second quarter 2021 financial results on Monday, August 9, after the close of the U.S. financial markets.
Jun 28, 2021 07:00 am ET
SNDX-5613 Granted FDA Fast Track Designation for the Treatment of Relapsed/Refractory Acute Leukemias
WALTHAM, Mass., June 28, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to SNDX-5613 for the treatment of adult and pediatric patients with relapsed or refractory acute leukemias harboring a mixed lineage leukemia rearranged (MLLr) or nucleophosmin (NPM1) mutation. SNDX-5613 is the Company's highly selective, oral menin inhibitor.
Feb 24, 2021 06:00 am ET
Syndax Announces Participation at Two Upcoming Investor Conferences
WALTHAM, Mass., Feb. 24, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in two upcoming virtual investor conferences:
Dec 18, 2020 06:00 am ET
Syndax Pharmaceuticals To Be Added to the NASDAQ Biotechnology Index
WALTHAM, Mass., Dec. 18, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that the Company has been selected for addition to the NASDAQ Biotechnology Index® (NASDAQ: ^NBI), effective prior to market open on Monday, December 21, 2020.
Dec 11, 2020 03:30 pm ET
Syndax Announces Closing of Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares
WALTHAM, Mass, Dec. 11, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the closing of its previously announced underwritten public offering of 6,250,000 shares of its common stock, which includes the exercise in full of the underwriters' option to purchase 815,217 additional shares, at a price to the public of $23.00 per share. The gross proceeds to Syndax from this offering, before deducting underwriting discounts and commissi
Dec 09, 2020 05:30 am ET
Syndax Announces Pricing of Public Offering of Common Stock
WALTHAM, Mass., Dec. 9, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced today the pricing of an underwritten public offering of 5,434,783 shares of its common stock at a price to the public of $23.00 per share. The gross proceeds to Syndax from this offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $125 million. The offering is expected to close on
Dec 07, 2020 03:31 pm ET
Syndax Announces Proposed Public Offering of Common Stock
WALTHAM, Mass., Dec. 7, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it plans to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. There can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. Syndax also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of
Dec 06, 2020 11:30 am ET
Syndax Pharmaceuticals Announces Additional Positive Data from Phase 1 Trial of Axatilimab in Patients with cGVHD
WALTHAM, Mass., Dec. 6, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced updated data from the Company's Phase 1 trial of axatilimab, its anti-CSF-1R monoclonal antibody, in patients with chronic graft versus host disease (cGVHD). The data will be featured today during an oral presentation at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition. A copy of the presentation will be available via Syndax's webs
Nov 30, 2020 06:00 am ET
Syndax Pharmaceuticals to Host Axatilimab Conference Call and Webcast Featuring Two cGVHD Experts
WALTHAM, Mass., Nov. 30, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will host a conference call and webcast featuring two experts in the science and treatment of chronic graft versus host disease (cGVHD) on Sunday, December 6, 2020 at 2:00 p.m. E.T. The event will take place following an oral presentation highlighting updated data from the Company's Phase 1 trial of axatilimab, its anti-CSF-1R monoclonal antibody, i
Nov 11, 2020 06:00 am ET
Syndax Announces Presentation at Stifel 2020 Virtual Healthcare Conference
WALTHAM, Mass., Nov. 11, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Briggs W. Morrison, M.D., Chief Executive Officer of Syndax, will present at the Stifel 2020 Virtual Healthcare Conference on Wednesday, November 18, 2020 at 1:20 p.m. ET.
Nov 04, 2020 03:05 pm ET
Syndax Pharmaceuticals to Present Updated Data from Phase 1 Trial of Axatilimab in cGVHD During Oral Session at the 62nd ASH Annual Meeting
WALTHAM, Mass., Nov. 4, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that updated data from the Company's Phase 1 trial of axatilimab, its anti-CSF-1R monoclonal antibody, in patients with chronic graft versus host disease (cGVHD) will be featured during an oral presentation at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition being held December 5 – 8, 2020 in a virtual format.
Nov 02, 2020 03:05 pm ET
Syndax Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Clinical and Business Update
WALTHAM, Mass., Nov. 2, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the third quarter ended September 30, 2020. In addition, the Company provided a clinical and business update.
Oct 26, 2020 07:00 am ET
Syndax to Announce Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 2, 2020
WALTHAM, Mass., Oct. 26, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its third quarter 2020 financial results on Monday, November 2, after the close of the U.S. financial markets.
Aug 06, 2020 04:05 pm ET
Syndax Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Clinical and Business Update
WALTHAM, Mass., Aug. 6, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the second quarter ended June 30, 2020. In addition, the Company provided a clinical and business update.
Aug 03, 2020 07:00 am ET
Syndax Announces Participation in BTIG Virtual Biotechnology Conference
WALTHAM, Mass., Aug. 3, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate virtually in the BTIG Biotechnology Conference on Monday, August 10, 2020 at 12:00 p.m. ET.
Jul 30, 2020 07:00 am ET
Syndax to Announce Second Quarter 2020 Financial Results and Host Conference Call and Webcast on August 6, 2020
WALTHAM, Mass., July 30, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its second quarter 2020 financial results on Thursday, August 6, after the close of the U.S. financial markets.
Jul 07, 2020 07:00 am ET
Syndax Pharmaceuticals Appoints Daphne Karydas as Chief Financial Officer
WALTHAM, Mass., July 7, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the appointment of Daphne Karydas as Chief Financial Officer, effective July 13, 2020. Ms. Karydas, who brings to Syndax nearly 20 years of financial experience in the biopharmaceutical industry, most recently served as Senior Vice President of Corporate Financial Planning & Analysis and Strategy at Allergan, where she oversaw the company's long-term fina
May 21, 2020 04:35 pm ET
ECOG-ACRIN Provides Syndax Pharmaceuticals With Results of Phase 3 E2112 Trial of Entinostat Plus Exemestane in Patients with HR+, HER2- Breast Cancer
WALTHAM, Mass., May 21, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX) today announced receipt of the final results of E2112, the Phase 3 clinical trial conducted by ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and sponsored by the National Cancer Institute (NCI), that evaluated the investigational compound entinostat, Syndax's class I HDAC inhibitor, plus exemestane in patients with advanced hormone receptor positive, human epidermal growth factor receptor 2 negative (HR+, HER2-) breast cancer who have progressed on a non-steroidal aromatase inhibitor. The trial did not a
May 12, 2020 04:05 pm ET
Syndax Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
WALTHAM, Mass., May 12, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the closing of its previously announced underwritten public offering of 6,388,889 shares of its common stock at a price to the public of $18.00 per share. This includes the exercise in full by the underwriters of their option to purchase up to 833,333 additional shares of common stock. The aggregate gross proceeds to Syndax from this offering were approxi
May 07, 2020 04:05 pm ET
Syndax Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Clinical and Business Update
WALTHAM, Mass., May 7, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the first quarter ended March 31, 2020. In addition, the Company provided a clinical and business update.
Apr 30, 2020 07:51 am ET
Syndax Announces Pricing of Public Offering of Common Stock
WALTHAM, Mass., April 30, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today the pricing of an underwritten public offering of 5,555,556 shares of its common stock at a price to the public of $18.00 per share. The gross proceeds to Syndax from this offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $100 million. The offering is expected to close on
Apr 29, 2020 04:35 pm ET
Syndax Announces Proposed Public Offering of Common Stock
WALTHAM, Mass., April 29, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it plans to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. There can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. Syndax also expects to grant the underwriters a 30-day option to purchase up to an additional 15%
Apr 27, 2020 04:05 pm ET
Syndax Pharmaceuticals Announces Preclinical Profile and Initial Phase 1 Data Demonstrating Clinical Activity of Menin Inhibitor SNDX-5613 in Adults with Relapsed/Refractory Acute Leukemias
WALTHAM, Mass., April 27, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today presents preclinical and initial clinical data for SNDX-5613, the Company's potent, highly selective oral menin inhibitor. The oral presentation will be featured during the New Drugs on the Horizon session at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting I. The New Drugs on the Horizon session will take place today at 4:50 p.m. ET a
Apr 14, 2020 07:00 am ET
Syndax Pharmaceuticals Announces Three Presentations at the 2020 American Association for Cancer Research Virtual Annual Meeting
WALTHAM, Mass., April 14, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced three presentations at the upcoming 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting being held April 27 - 28, 2020.
Nov 07, 2019 03:05 pm ET
Syndax Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Clinical and Business Update
WALTHAM, Mass., Nov. 7, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the third quarter ended September 30, 2019. In addition, the Company provided a clinical and business update. As of September 30, 2019, Syndax had $72.2 million in cash, cash equivalents and short-term investments.
Nov 06, 2019 06:00 am ET
Syndax Announces First Patient Dosed in Phase 1/2 AUGMENT-101 Trial of SNDX-5613 for the Treatment of Adults with Relapsed/Refractory Acute Leukemias
WALTHAM, Mass., Nov. 6, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that the first patient has been dosed in AUGMENT-101, a Phase 1/2 clinical trial evaluating SNDX-5613, Syndax's potent, highly selective oral Menin inhibitor, in patients with relapsed/refractory (R/R) acute leukemias.
Oct 31, 2019 07:00 am ET
Syndax to Announce Third Quarter 2019 Financial Results and Host Conference Call and Webcast on November 7, 2019
WALTHAM, Mass., Oct. 31, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its third quarter 2019 financial results on Thursday, November 7, after the close of the U.S. financial markets.
Aug 28, 2019 07:00 am ET
Syndax Announces Participation at Four Upcoming Investor Conferences
WALTHAM, Mass., Aug. 28, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of the management team will participate in four upcoming investor conferences. The details for the four conferences are:
Aug 07, 2019 04:05 pm ET
Syndax Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Clinical and Business Update
WALTHAM, Mass., Aug. 7, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the second quarter ended June 30, 2019. In addition, the Company provided a clinical and business update. As of June 30, 2019, Syndax had $80.5 million in cash, cash equivalents and short-term investments.
Aug 05, 2019 07:00 am ET
Syndax to Participate in the BTIG Biotechnology Conference
WALTHAM, Mass., Aug. 5, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Briggs W. Morrison, M.D., Chief Executive Officer of Syndax, will participate in a panel discussion on targeted oncology therapies at the BTIG Biotechnology Conference on Monday, August 12, 2019 at 4:00 p.m. ET at the St. Regis New York.
Jul 31, 2019 07:00 am ET
Syndax to Announce Second Quarter 2019 Financial Results and Host Conference Call and Webcast on August 7, 2019
WALTHAM, Mass., July 31, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its second quarter 2019 financial results on Wednesday, August 7, after the close of the U.S. financial markets.
Jul 10, 2019 07:00 am ET
Syndax Pharmaceuticals Announces FDA Clearance of IND Application for Targeted Menin Inhibitor SNDX-5613 for Relapsed/Refractory Acute Leukemias
WALTHAM, Mass., July 10, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application to begin a Phase 1/2 trial for SNDX-5613, a targeted Menin inhibitor, in patients with relapsed/refractory (R/R) acute leukemias.
May 14, 2019 07:00 am ET
Syndax to Present at the UBS Global Healthcare Conference
WALTHAM, Mass., May 14, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Briggs W. Morrison, M.D., Chief Executive Officer of Syndax, will present at the UBS Global Healthcare Conference on Tuesday, May 21, 2019 at 10:30 a.m. ET at the Grand Hyatt New York.
May 06, 2019 04:05 pm ET
Syndax Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Clinical and Business Update
WALTHAM, Mass., May 6, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the first quarter ended March 31, 2019. In addition, the Company provided a clinical and business update. As of March 31, 2019, Syndax had $92.7 million in cash, cash equivalents and short-term investments.
Apr 29, 2019 07:00 am ET
Syndax to Announce First Quarter 2019 Financial Results and Host Conference Call and Webcast on May 6, 2019
WALTHAM, Mass., April 29, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its first quarter 2019 financial results on Monday, May 6, after the close of the U.S. financial markets.
Apr 11, 2019 07:55 am ET
Research Report Identifies Chimerix, Evolent Health, ABIOMED, Syndax Pharmaceuticals, Independence Realty Trust, and Selecta Biosciences with Renewed Outlook — Fundamental Analysis, Calculating Forwar
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Chimerix, Inc. (NASDAQ:CMRX), Evolent Health, Inc (NYSE:EVH), ABIOMED,...
Apr 01, 2019 10:33 am ET
Syndax Pharmaceuticals Presents Updated Phase 2 Data from ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA® (pembrolizumab) at the American Association for Cancer Research 2019 Annual Meeti
WALTHAM, Mass., April 1, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the presentation of updated findings from the melanoma and non-small cell lung cancer (NSCLC) cohorts of ENCORE 601, the Company's Phase 1b/2 trial evaluating the efficacy and safety of entinostat, its once-weekly, oral, small molecule, class I HDAC inhibitor, in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 (programmed death receptor-1) the
Mar 27, 2019 07:00 am ET
Syndax Announces $26.2 Million Offering of Common Stock and Warrants
WALTHAM, Mass., March 27, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax" or the "Company") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it has entered into an agreement with Biotechnology Value Fund, L.P. ("BVF") and other leading life sciences investors for the purchase of 4,366,666 shares of common stock at a purchase price of $6.00 per share, representing a premium of 30% to the share price as of market close on Tuesday, March 26, as well as warrants to purchase up to 2,183,331 shares of
Mar 07, 2019 03:05 pm ET
Syndax Pharmaceuticals Reports Fourth Quarter 2018 Financial Results and Provides Clinical and Business Update
WALTHAM, Mass., March 7, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the fourth quarter ended December 31, 2018. In addition, the Company provided a clinical and business update. As of December 31, 2018, Syndax had $80.9 million in cash, cash equivalents and short-term investments.
Mar 06, 2019 06:00 am ET
Syndax to Present at the Cowen 39th Annual Health Care Conference
WALTHAM, Mass., March 6, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Briggs W. Morrison, M.D., Chief Executive Officer of Syndax, will present at the Cowen 39th Annual Health Care Conference on Wednesday, March 13, 2019 at 11:20 a.m. ET at the Boston Marriott Copley Place.
Feb 28, 2019 06:00 am ET
Syndax to Announce Fourth Quarter and Year-end 2018 Financial Results and Host Conference Call and Webcast on March 7, 2019
WALTHAM, Mass., Feb. 28, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its fourth quarter 2018 financial results on Thursday, March 7, after the close of the U.S. financial markets.
Feb 27, 2019 03:47 pm ET
Syndax Announces Clinical Data from its Entinostat Immuno-oncology Program Selected for Two Oral Presentations at the American Association for Cancer Research Annual Meeting 2019
WALTHAM, Mass., Feb. 27, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced two oral presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting being held March 29 - April 3, 2019 in Atlanta, Georgia.
Feb 12, 2019 07:55 am ET
New Research: Key Drivers of Growth for Cronos Group, Spectrum Brands, Black Hills, Entercom Communications, CSS Industries, and Syndax Pharmaceuticals — Factors of Influence, Major Initiatives and Su
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Cronos Group Inc. (NASDAQ:CRON), Spectrum Brands Holdings Inc....
Jan 07, 2019 06:00 am ET
Syndax Highlights 2019 Clinical and Corporate Outlook
WALTHAM, Mass., Jan. 7, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today provided a 2019 clinical and corporate outlook.
Dec 03, 2018 09:00 am ET
Syndax Pharmaceuticals Announces Presentation of Preclinical Data from Menin-MLL Program at the 60th American Society of Hematology Annual Meeting
WALTHAM, Mass., Dec. 3, 2018 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the presentation of preclinical data from the Company's Menin-Mixed Lineage Leukemia (MLL) inhibitor program at the 60th American Society of Hematology (ASH) Annual Meeting in San Diego, California.
Nov 12, 2018 08:50 am ET
Investor Expectations to Drive Momentum within CommScope Holding, AMC Networks, Henry Schein, Lindblad Expeditions, Apple Hospitality REIT, and Syndax Pharmaceuticals — Discovering Underlying Factors
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of CommScope Holding Company, Inc. (NASDAQ:COMM), AMC Networks Inc....
Nov 05, 2018 03:05 pm ET
Syndax Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Clinical and Business Update
WALTHAM, Mass., Nov. 5, 2018 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the third quarter ended September 30, 2018. In addition, the Company provided a clinical and business update. As of September 30, 2018, Syndax had $89.6 million in cash, cash equivalents and short-term investments.
Nov 01, 2018 04:05 pm ET
Syndax Pharmaceuticals Announces Presentations at the 60th American Society of Hematology Annual Meeting
WALTHAM, Mass., Nov. 1, 2018 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that the Company's Menin-MLLr program will be featured during two presentations at the 60th American Society of Hematology (ASH) Annual Meeting being held December 1-4, 2018 in San Diego, California.
Oct 29, 2018 07:00 am ET
Syndax to Announce Third Quarter 2018 Financial Results and Host Conference Call and Webcast on November 5, 2018
WALTHAM, Mass., Oct. 29, 2018 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its third quarter 2018 financial results on Monday, November 5, after the close of the U.S. financial markets.
Oct 25, 2018 04:05 pm ET
Syndax to Host Conference Call to Provide Update on the Phase 3 Breast Cancer Trial (E2112) and to Announce its Registration Trial of Entinostat with Keytruda in PD-(L)1 Refractory Non-Small Cell Lung
WALTHAM, Mass., Oct. 25, 2018 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced it will provide an update on E2112, its NCI-sponsored, ECOG-ACRIN led pivotal trial of entinostat plus exemestane in hormone receptor positive, human epidermal growth factor receptor 2 negative (HR+, HER2-) breast cancer as well as its registration strategy for entinostat in combination with KEYTRUDA® (pembrolizumab) in patients with non-small cell lung canc
Oct 18, 2018 08:35 am ET
Report: Exploring Fundamental Drivers Behind Syndax Pharmaceuticals, Arconic, Del Taco Restaurants, Aerohive Networks, KalVista Pharmaceuticals, and Adtalem Global Education — New Horizons, Emerging T
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX), Arconic Inc. (NYSE:ARNC),...
Sep 26, 2018 07:00 am ET
Syndax to Present at the 2018 Cantor Global Healthcare Conference
WALTHAM, Mass., Sept. 26, 2018 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Briggs W. Morrison, M.D., Chief Executive Officer of Syndax, will present at the 2018 Cantor Global Healthcare Conference on Wednesday, October 3, 2018 at 9:10 a.m. ET at the InterContinental New York Barclay Hotel.
Sep 25, 2018 04:05 pm ET
Syndax Announces Changes to its Board of Directors
WALTHAM, Mass., Sept. 25, 2018 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the appointment of Jennifer Jarrett and William Meury to its Board of Directors, effective today. Ms. Jarrett and Mr. Meury will succeed Luke Evnin, Ph.D. and Henry Chen, who resigned as active members of the Syndax Board of Directors, effective today.
Sep 24, 2018 04:05 pm ET
Syndax Announces Updated Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA® (pembrolizumab) in Non-Small Cell Lung Cancer
WALTHAM, Mass., Sept. 24, 2018 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced updated results from the ongoing ENCORE 601 cohort enrolling non-small cell lung cancer (NSCLC) patients previously treated with both chemotherapy and PD-(L)1 therapy. The oral presentation titled, "Efficacy/Safety of Entinostat (ENT) and Pembrolizumab (PEMBRO) in NSCLC Patients Previously Treated with Anti-PD-(L)1 Therapy," was presented by Matthew D. Hel
Sep 05, 2018 05:00 pm ET
Syndax to Present at the International Association for the Study of Lung Cancer 19th World Conference on Lung Cancer
WALTHAM, Mass., Sept. 5, 2018 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that data from the PD-(L)1 refractory non-small cell lung cancer (NSCLC) cohort of ENCORE 601 will be presented at the upcoming International Association for the Study of Lung Cancer (IASLC) 19th World Conference on Lung Cancer (WCLC) being held September 23-26, 2018 in Toronto, Canada. ENCORE 601 is a Phase 1b/2 trial evaluating the efficacy and safety of
Aug 28, 2018 07:00 am ET
Syndax Announces Participation at Three Upcoming Investor Conferences
WALTHAM, Mass., Aug. 28, 2018 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of the management team will participate in three upcoming investor conferences. The details for the three conferences are:
Aug 27, 2018 08:15 am ET
New Research: Key Drivers of Growth for REGENXBIO, Syndax Pharmaceuticals, Rowan Companies, CTS, Basic Energy Services, and Impinj — Factors of Influence, Major Initiatives and Sustained Production
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of REGENXBIO Inc. (NASDAQ:RGNX), Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX),...
Aug 07, 2018 04:05 pm ET
Syndax Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Clinical and Business Update
WALTHAM, Mass., Aug. 7, 2018 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the second quarter ended June 30, 2018. In addition, the Company provided a clinical and business update. As of June 30, 2018, Syndax had $98.4 million in cash, cash equivalents and short-term investments.
Jul 31, 2018 07:00 am ET
Syndax to Announce Second Quarter 2018 Financial Results and Host Conference Call and Webcast on August 7, 2018
WALTHAM, Mass., July 31, 2018 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its second quarter 2018 financial results on Tuesday, August 7, 2018, after the close of the U.S. financial markets.
Jun 22, 2018 07:35 am ET
Research Report Identifies NetScout, Waterstone Financial, Lindblad Expeditions, Syndax Pharmaceuticals, Hospitality Properties Trust, and NewMarket with Renewed Outlook — Fundamental Analysis, Calcul
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of NetScout Systems, Inc. (NASDAQ:NTCT), Waterstone Financial, Inc....
May 30, 2018 07:00 am ET
Syndax Pharmaceuticals Announces Participation at Two Upcoming Investor Conferences
WALTHAM, Mass., May 30, 2018 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of the management team will participate in two upcoming investor conferences. The details for the two conferences are:
May 17, 2018 07:00 am ET
Syndax Announces Updated Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA® (pembrolizumab)
WALTHAM, Mass., May 17, 2018 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced updated results from multiple cohorts of the ongoing Phase 2 ENCORE 601 trial of entinostat in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 (programmed death receptor-1) therapy. This data will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting being held June 1-5, 2018 in Chicago, Illinois.
May 08, 2018 04:05 pm ET
Syndax Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Clinical and Business Update
WALTHAM, Mass., May 8, 2018 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the first quarter ended March 31, 2018. In addition, the Company provided a clinical and business update. As of March 31, 2018, Syndax had $113.2 million in cash, cash equivalents and short-term investments.
May 03, 2018 07:40 am ET
Detailed Research: Economic Perspectives on Park-Ohio, WageWorks, Parker-Hannifin, Sturm, Ruger, Syndax Pharmaceuticals, and Fastenal — What Drives Growth in Today's Competitive Landscape
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Park-Ohio Holdings Corp. (NASDAQ:PKOH), WageWorks, Inc. (NYSE:WAGE),...
May 01, 2018 07:00 am ET
Syndax to Announce First Quarter 2018 Financial Results and Host Conference Call and Webcast on May 8, 2018
WALTHAM, Mass., May 1, 2018 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its first quarter 2018 financial results on Tuesday, May 8, 2018, after the close of the U.S. financial markets.
Apr 25, 2018 04:05 pm ET
Syndax Pharmaceuticals Announces Presentations at the 2018 American Society of Clinical Oncology Annual Meeting
WALTHAM, Mass., April 25, 2018 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced five poster presentations at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting being held June 1-5, 2018 in Chicago, Illinois.
Apr 13, 2018 07:00 am ET
Syndax to Present at the 2018 American Association for Cancer Research Annual Meeting
WALTHAM, Mass., April 13, 2018 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced twelve oral and poster presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting being held April 14-18, 2018 in Chicago, Illinois.
Mar 19, 2018 08:00 am ET
Analysis: Positioning to Benefit within ICF International, Invitae, Encore Wire, Alexandria Real Estate Equities, Syndax Pharmaceuticals, and Vical — Research Highlights Growth, Revenue, and Consolida
NEW YORK, March 19, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ICF International, Inc. (NASDAQ:ICFI), Invitae Corporation...
Mar 05, 2018 03:05 pm ET
Syndax Pharmaceuticals Reports Fourth Quarter 2017 Financial Results and Provides Clinical and Business Update
WALTHAM, Mass., March 5, 2018 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the fourth quarter ended December 31, 2017. In addition, the Company provided a clinical and business update. As of December 31, 2017, Syndax had $133.2 million in cash, cash equivalents and short-term investments.
Mar 05, 2018 06:00 am ET
Syndax Pharmaceuticals Announces Participation at Two Upcoming Investor Conferences
WALTHAM, Mass., March 5, 2018 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Briggs W. Morrison, M.D., Chief Executive Officer of Syndax, will participate in two upcoming investor conferences. The details for the two conferences are:
Feb 26, 2018 06:00 am ET
Syndax to Announce Fourth Quarter and Year-end 2017 Financial Results and Host Conference Call and Webcast on March 5, 2018
WALTHAM, Mass., Feb. 26, 2018 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its fourth quarter 2017 financial results on Monday, March 5, 2018, after the close of the U.S. financial markets.
Feb 22, 2018 06:00 am ET
Syndax Announces Presentations at the 2018 American Association for Cancer Research Annual Meeting
WALTHAM, Mass., Feb. 22, 2018 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced eight presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting being held April 14-18, 2018 in Chicago, Illinois.
Feb 01, 2018 06:00 am ET
Syndax Announces Immuno-Oncology Clinical Trial Collaboration with AstraZeneca
WALTHAM, Mass., Feb. 1, 2018 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced a new clinical collaboration with AstraZeneca to evaluate the safety and efficacy of AstraZeneca's durvalumab, a human monoclonal antibody directed against programmed death-ligand 1 (PD-L1), in combination with SNDX-6352, Syndax's monoclonal antibody inhibitor of Colony-Stimulating Factor 1 Receptor (CSF1R), across a variety of solid tumors.
Jan 10, 2018 06:00 am ET
Syndax Pharmaceuticals Announces Clinical Collaboration to Evaluate Entinostat in Combination with anti-PD-L1 Cancer Immunotherapy in Breast Cancer
WALTHAM, Mass., Jan. 10, 2018 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing entinostat and SNDX-6352 in multiple cancer indications, today announced a new clinical collaboration with Genentech, a member of the Roche Group. As part of the collaboration, the two companies will evaluate the combination of Syndax's entinostat, an oral, small molecule, class I HDAC inhibitor, and Genentech's programmed cell death ligand 1 (PD-L1) blocking antibody, atezolizumab (TECENTRIQ®), in patients with sec
Jan 09, 2018 08:30 am ET
Investor Expectations to Drive Momentum within Cutera, Matrix Service, PRA Group, Materion, Second Sight Medical Products, and Syndax Pharmaceuticals — Discovering Underlying Factors of Influence
NEW YORK, Jan. 09, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Cutera, Inc. (NASDAQ:CUTR), Matrix Service Company...
Nov 11, 2017 03:00 pm ET
Syndax Pharmaceuticals Announces Presentation of Data from Immuno-oncology Clinical Trials at the Society for Immunotherapy of Cancer 32nd Annual Scientific Meeting
WALTHAM, Mass., Nov. 11, 2017 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing entinostat and SNDX-6352 in multiple cancer indications, today announced results from the non-small cell lung cancer (NSCLC) and melanoma cohorts of ENCORE 601, an open-label, Phase 1b/2 clinical trial employing a Simon two-stage design to evaluate the combination of entinostat, the Company's class I selective HDAC inhibitor, plus Merck's (also known as MSD outside of the United States and Canada) anti-PD-1 (program
Nov 07, 2017 04:05 pm ET
Syndax Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Clinical and Business Update
WALTHAM, Mass., Nov. 7, 2017 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing entinostat and SNDX-6352 in multiple cancer indications, today reported its financial results for the third quarter ended September 30, 2017. In addition, the Company provided a clinical and business update. As of September 30, 2017, Syndax had $120.6 million in cash, cash equivalents and short-term investments.
Nov 07, 2017 08:00 am ET
Syndax to Present at the SITC 32nd Annual Scientific Meeting
WALTHAM, Mass., Nov. 7, 2017 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing entinostat and SNDX-6352 in multiple cancer indications, today announced five presentations at the upcoming Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting being held November 8-12, 2017 in National Harbor, Maryland.
Oct 31, 2017 08:00 am ET
Syndax to Announce Third Quarter 2017 Financial Results and Host Conference Call and Webcast on November 7, 2017
WALTHAM, Mass., Oct. 31, 2017 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing entinostat and SNDX-6352 in multiple cancer indications, announced today that it will release its third quarter 2017 financial results on Tuesday, November 7, 2017, after the close of the U.S. financial markets.
Oct 17, 2017 08:01 am ET
Syndax Announces $25 Million Registered Direct Offering of Common Stock
WALTHAM, Mass., Oct. 17, 2017 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing entinostat and SNDX-6352 in multiple cancer indications, today announced that it has agreed to sell 2,021,018 shares of its common stock to Biotechnology Value Fund, L.P. and certain of its affiliates ("BVF") in a registered direct offering. Syndax anticipates aggregate gross proceeds from the offering will be approximately $25.0 million based on the offering price of $12.37 per share, representing the closing pric
Oct 17, 2017 08:00 am ET
Syndax Expands Pipeline with Exclusive Worldwide License to Allergan's Portfolio of Menin-MLL Inhibitors
WALTHAM, Mass., Oct. 17, 2017 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing entinostat and SNDX-6352 in multiple cancer indications, today announced that it has entered into an exclusive worldwide license agreement with Vitae Pharmaceuticals, Inc., a subsidiary of Allergan plc, for a portfolio of preclinical, orally-available small molecule inhibitors of the interaction of Menin with the Mixed Lineage Leukemia ("MLL") protein. These compounds have potential application in the treatment of a
Oct 05, 2017 08:00 am ET
Syndax Announces Dosing of First Patient in Pivotal Trial of Entinostat for the Treatment of Advanced or Recurrent Breast Cancer in Japan by Partner Kyowa Hakko Kirin
WALTHAM, Mass., Oct. 5, 2017 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing entinostat and SNDX-6352 in multiple cancer indications, today announced that Kyowa Hakko Kirin Co., Ltd (Kyowa Hakko Kirin), its Japan and Korea sublicensee, has now dosed the first patient in a randomized, double-blind, placebo-controlled, pivotal Phase 2 trial of entinostat (designated KHK2375 by Kyowa Hakko Kirin), Syndax's oral Class-I histone deacetylase inhibitor, in combination with exemestane versus exemesta
Sep 20, 2017 08:00 am ET
Syndax Pharmaceuticals Announces Updated Presentation Time at the Cantor Fitzgerald Global Healthcare Conference
WALTHAM, Mass., Sept. 20, 2017 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing entinostat and SNDX-6352 in multiple cancer indications, today announced an update to the time of the Company's presentation at the Cantor Fitzgerald Global Healthcare Conference. Briggs W. Morrison, M.D., Chief Executive Officer of Syndax, will now present on September 25, 2017 at 11:30 am EDT at the InterContinental New York Barclay Hotel.
Aug 30, 2017 08:00 am ET
Syndax Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences
WALTHAM, Mass., Aug. 30, 2017 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing entinostat and SNDX-6352 in multiple cancer indications, today announced that Briggs W. Morrison, M.D., Chief Executive Officer of Syndax, will participate in three upcoming investor conferences. The details for the three conferences are:
Aug 10, 2017 05:05 pm ET
Syndax Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Clinical and Business Update
WALTHAM, Mass., Aug. 10, 2017 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing entinostat and SNDX-6352 in multiple cancer indications, today reported its financial results for the second quarter ended June 30, 2017. In addition, the Company provided a clinical and business update. As of June 30, 2017, Syndax had $130.0 million in cash, cash equivalents and short-term investments.
Aug 03, 2017 08:00 am ET
Syndax to Announce Second Quarter 2017 Financial Results and Host Conference Call and Webcast on August 10, 2017
WALTHAM, Mass., Aug. 3, 2017 /PRNewswire/ -- Syndax (Nasdaq: SNDX) announced today that it will release its second quarter 2017 financial results on Thursday, August 10, 2017, after the close of the U.S. financial markets.
Jul 11, 2017 05:05 pm ET
Preclinical Results Support Entinostat's Role in Targeting the Tumor Microenvironment to Enhance Immune Checkpoint Therapy
WALTHAM, Mass. and PHILADELPHIA and INDIANAPOLIS, July 11 2017 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing entinostat and SNDX-6352 in multiple cancer indications, in collaboration with The Wistar Institute and Indiana University Melvin and Bren Simon Cancer Center, today announced the publication of a preclinical report demonstrating that entinostat, Syndax's oral, Class-I histone deacetylase inhibitor, enhances the antitumor effect of PD-1 (programmed death receptor-1) blockade through t
May 24, 2017 07:22 pm ET
Syndax Prices Public Offering of Common Stock
WALTHAM, Mass., May 24, 2017 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX) announced today the pricing of an underwritten public offering of 3,750,000 shares of its common stock at a price to the public of $13.25 per share. The gross proceeds to Syndax from this offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $49.7 million. The offering is expected to close on May 31, 2017, subject to customary closing conditions. Additionally, Syndax granted the underwriters a 30-day option to purchase up ...
May 23, 2017 04:48 pm ET
Syndax Announces Proposed Public Offering of Common Stock
WALTHAM, Mass., May 23, 2017 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX) announced today that it plans to offer and sell, subject to market and other conditions, $50 million of its common stock in an underwritten public offering. There can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. Syndax also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares sold in the public offering. All of the shares in the proposed offering are to be sold by Syndax....
May 17, 2017 05:07 pm ET
Syndax Announces Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA® (pembrolizumab) for the Treatment of Advanced Melanoma
-31% objective response rate for first stage of the Phase 2 melanoma cohort of ENCORE 601-...
May 08, 2017 04:05 pm ET
Syndax Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Clinical and Business Update
Enrollment of second stage of melanoma cohort in Phase 2 ENCORE 601 trial proceeding ahead of schedule; expected to be completed in the third quarter...
May 01, 2017 07:00 am ET
Syndax to Announce First Quarter 2017 Financial Results and Host Conference Call and Webcast on May 8, 2017
WALTHAM, Mass., May 01, 2017 (GLOBE NEWSWIRE) -- Syndax (Nasdaq:SNDX) announced today that it will release its first quarter 2017 financial results on Monday, May 8, 2017, after the close of the U.S. financial markets....
Apr 20, 2017 04:05 pm ET
Syndax Announces Entinostat Data to be Presented at the 2017 American Society of Clinical Oncology Annual Meeting
WALTHAM, Mass., April 20, 2017 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing entinostat and SNDX-6352 in multiple cancer indications, today announced a poster presentation highlighting entinostat at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting being held June 2-6, 2017 in Chicago, Illinois. The poster will feature data from the ongoing phase 2 ENCORE 601 trial of entinostat in combination with KEYTRUDA® (pembrolizumab) for the treatment of advanced melanoma ...
Mar 02, 2017 04:05 pm ET
Syndax Pharmaceuticals Reports Fourth Quarter and Year-end 2016 Financial Results and Provides Clinical and Business Update
Encore 601 refractory melanoma cohort to proceed to second stage of Phase 2; pre-specified objective response criteria satisfied...
Jan 31, 2017 07:00 am ET
Syndax Appoints Lisa M. Coussens, Ph.D., to Scientific Advisory Board
WALTHAM, Mass., Jan. 31, 2017 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. ("Syndax," the “Company” or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in multiple cancer indications, today announced the appointment of Lisa M. Coussens, Ph.D., to its Scientific Advisory Board....
Nov 10, 2016 04:01 pm ET
Syndax Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Business Update
Execution on clinical timelines and advancement of oncology programs continues with initiation of:...
Oct 28, 2016 07:00 am ET
Syndax to Announce Third Quarter 2016 Financial Results and Host Conference Call and Webcast on November 10, 2016
WALTHAM, Mass., Oct. 28, 2016 (GLOBE NEWSWIRE) -- Syndax (Nasdaq:SNDX) announced today that it will release its third quarter 2016 financial results on Thursday, November 10, 2016, after the close of the U.S. financial markets....
Sep 06, 2016 07:00 am ET
Syndax Pharmaceuticals Announces Participation at Four Upcoming Investor Conferences
WALTHAM, Mass., Sept. 06, 2016 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in multiple cancer indications, today announced its planned participation in four upcoming investor conferences. The details for the four conferences are:...
Aug 09, 2016 06:30 am ET
Syndax Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Business Update
Expanded pipeline with potentially best-in-class, IND-ready anti-CSF-1R antibody...
Jul 27, 2016 07:00 am ET
Syndax Appoints Leading Experts to Scientific Advisory Board (SAB)
WALTHAM, Mass., July 27, 2016 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on the development of novel anti-cancer therapies, announced the appointment of seven leading oncology experts to its Scientific Advisory Board (SAB). The SAB is expected to serve as a strategic network of scientific and clinical experts to Syndax as the company progresses the development of entinostat in multiple cancer indications and initiates clinical development of SNDX-6352, a CSF-1R targeted antibody. The SAB is also expected to be an inte...
Jul 20, 2016 04:01 pm ET
Syndax to Announce Second Quarter 2016 Financial Results and Host Conference Call and Webcast on August 9, 2016
WALTHAM, Mass., July 20, 2016 (GLOBE NEWSWIRE) -- Syndax (Nasdaq:SNDX) announced today that it will release its second quarter 2016 financial results on Tuesday, August 9, 2016, before the opening of the U.S. financial markets....
Jul 07, 2016 07:00 am ET
Syndax Pharmaceuticals to Present at the Cantor Fitzgerald 2nd Annual Healthcare Conference
WALTHAM, Mass., July 07, 2016 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat as a combination therapy across multiple cancer indications, today announced that Chief Executive Officer, Briggs Morrison, M.D., will present at the Cantor Fitzgerald 2nd Annual Healthcare Conference on July 13, 2016 at 2:00 pm EDT at Le Parker Meridien Hotel in New York, New York....
Jul 06, 2016 07:00 am ET
Syndax Expands Pipeline With Exclusive Worldwide License Agreement for UCB’s Colony Stimulating Factor 1 Receptor (CSF-1R) Antibody Program
WALTHAM, Mass., July 06, 2016 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat in multiple cancer indications, today announced that it has entered into an exclusive worldwide license agreement with UCB for UCB6352, an IND-ready anti-CSF-1R monoclonal antibody, which is expected to begin clinical trials in 2016....
Jun 14, 2016 07:00 am ET
Syndax Pharmaceuticals to Present at the JMP Securities Life Sciences Conference
WALTHAM, Mass., June 14, 2016 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat broadly as a combination therapy across multiple cancer indications, today announced that President and Chief Operating Officer, Michael A. Metzger, will present at the JMP Securities Life Sciences Conference on June 22, 2016 at 12:30 p.m. EDT at the St. Regis Hotel in New York City....
May 18, 2016 05:20 pm ET
Entinostat Data to be Highlighted at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting
WALTHAM, Mass., May 18, 2016 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat in multiple cancer indications, today announced that clinical data from the National Cancer Institute’s Cancer Therapy Evaluation Program (NCI-CTEP) will be presented at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO), which is being held from June 3 to June 7, 2016 in Chicago, Illinois....
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.